Vaccitech Limited: T cell immunotherapy company developing products for prevention and treatment of infectious diseases (ID) and cancer via T cell induction – spinout from Jenner Institute at University of Oxford. Proprietary ChAdOx (prime) and MVA (boost) technology platform induces and maintains CD8+ T-cells at the maximum levels published to date. Ph1/2 for HPV and HBV immunotherapies initiating 1H20. Two cancer immunotherapy programs (personalized vaccine and MAGE-NYESO therapeutics) enter the clinic in 2020. Two ChAdOx1 vaccines for coronaviruses with Oxford Univ funded by CEPI – COVID-19 (announced 3/10/20) and MERS (Ph.1 complete). Fast, scalable manufacturing platforms in proprietary cell lines. $150M funding at Jenner Institute and company raised $48M since formation in 2016 from leading investors including GV (formerly Google Ventures), Sequoia China and Oxford Sciences Innovation.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Infectious Disease, Oncology
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Vaccine
Website:
Address:
The Schrodinger Building, Heatley Road
The Oxford Science Park
Oxford, OX4 4GE
United Kingdom

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Summer 2020 NYC Private Company Showcase

New York, NY, August 10, 2020